Business
LENZ Therapeutics Announces Commercial Product Availability of VIZZ™ in the United States
VIZZ sample distribution initiated nationwide to Eye Care Professionals Commercial product shipments to be initiated in October to consumers with broad
About this update from Lenz Therapeutics, Inc.
[{"type":"text","content":"\n VIZZ sample distribution initiated nationwide to Eye Care Professionals\n \n \n Commercial product shipments to be initiated in October to consumers with broad product availability by mid-Q4 2025\n \n \n VIZZ is the first and only aceclidine-based eye drop approved to improve near vision in adults with presbyopia for up to 10 hours, a condition impacting approximately 128 million adults in the United States\n \n \n SAN DIEGO, Calif., Sept. 30, 2025 /PRNewswire/ -- LENZ Therapeutics, Inc. (Nasdaq: LENZ or \"LENZ\" or the \"Company\"), today announced VIZZ (aceclidine ophthalmic solution) 1.44%, the first and only FDA-approved aceclidine-based eye drop for the treatment of presbyopia in adults, is now available. Professional product sample distribution by the sales force to optometrists and ophthalmologists has been initiated nationwide. Commercial product shipments will be initiated to consumers in October through our ePharmacy partner and is anticipated to be broadly available, including via retail pharmacies, by mid-Q4 2025. \n Experience the full interactive Multichannel News Release here: https://www.multivu.com/lenz-therapeutics/9355851-en-lenz-therapeutics-vizz-presbyopia-treatment\n \n https://www.multivu.com/lenz-therapeutics/image/9355851-Vizz_Logo_4C-Claire-Campbell.jpg\n \n \"We are thrilled to introduce VIZZ to the 128 million adults living with blurry near vision in the United States,\" said Eef Schimmelpennink, President and Chief Executive Officer of LENZ Therapeutics. \"The team has been preparing for this moment for months and worked tirelessly to enable the availability of product samples and commercial product following our FDA approval. Initial feedback and early brand awareness from the ECP community is extremely positive, and we feel well-positioned for a successful product launch, firmly establishing VIZZ as a Category of One for the treatment of presbyopia.\"\n VIZZ is powered by aceclidine, differentiated by its mechanism of action as a predominantly pupil-selective miotic that interacts with the iris, with minimal ciliary muscle stimulation. VIZZ contracts the iris sphincter muscle, resulting in a pinhole effect and uniquely achieves a sub-2mm pupil that extends depth of focus to significantly improve near vision without causing a myopic shift. In the CLARITY Phase 3 clinical trial, 93% of participant...